Clinical Trials Sponsored by Medicis Pharmaceutical Corporation

Total 1868 results

Medicis Pharmaceutical Corporation

Completed

A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.

Human Volunteer

United States
Northwestern University
Medicis Pharmaceutical Corporation

Completed

Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone

Forehead/Glabellar Rhytid Complexes

United States
Massachusetts General Hospital
Medicis Pharmaceutical Corporation

Completed

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

Rosacea

United States
The Maas Clinic
Medicis Pharmaceutical Corporation

Completed

Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study

Intrinsic Aging of Skin | Solar Elastosis

United States
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

China
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Novelwise Pharmaceutical Corporation

Recruiting

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Malignant Neoplasm | Malignant Neoplasm of Brain

Taiwan
Advancis Pharmaceutical Corporation

Completed

APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat

Tonsillitis | Pharyngitis

United States
Advancis Pharmaceutical Corporation

Completed

APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat

Tonsillitis | Pharyngitis | Sore Throat

United States, Canada
Advancis Pharmaceutical Corporation

Completed

APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat

Pharyngitis

United States
Acerus Pharmaceuticals Corporation

Recruiting

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

Hypogonadism

United States
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (COURSE)

Venous Thromboembolism

Poland, Bulgaria, Latvia, Lithuania, Ukraine
Acerus Pharmaceuticals Corporation

Completed

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

Female Sexual Dysfunction

United States
Acerus Pharmaceuticals Corporation

Completed

Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ (MyT)

Hypogonadism

Canada
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Asthma
Biotest Pharmaceuticals Corporation

Completed

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

Hepatitis B Virus Associated Liver Disease

United States
Acerus Pharmaceuticals Corporation

Completed

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

Male Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy of an Intranasal Testosterone Product

Hypogonadism

United States
Inotek Pharmaceuticals Corporation

Completed

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

Ocular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)

United States
Inotek Pharmaceuticals Corporation

Completed

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)

United States
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Asthma
Nephron Pharmaceuticals Corporation

Completed

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Female Orgasmic Disorder

United States, Canada, Australia
Acerus Pharmaceuticals Corporation

Completed

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

Hypogonadism

United States
Biotest Pharmaceuticals Corporation

Withdrawn

Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation (Nabi-HB-SC)

Hepatitis B, Chronic
Adamis Pharmaceuticals Corporation

Unknown

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Prostate Cancer

United States
Inotek Pharmaceuticals Corporation

Completed

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Inotek Pharmaceuticals Corporation

Completed

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

Health

United States
Inotek Pharmaceuticals Corporation

Completed

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Acute Myocardial Infarction

United States, Israel
Adamis Pharmaceuticals Corporation

Terminated

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Covid19

United States
Acerus Pharmaceuticals Corporation

Withdrawn

Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma

Asthma
Acerus Pharmaceuticals Corporation

Withdrawn

Influence of Administration Route of Testosterone on Male Fertility

Hypogonadism

Netherlands
Inotek Pharmaceuticals Corporation

Completed

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma (MATrX-1)

Ocular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)

United States
Inotek Pharmaceuticals Corporation

Terminated

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

Heart Diseases | Postoperative Complications

United States, Israel, Australia, India
Riverside Pharmacueticals Corporation

Completed

Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

Other

Canada
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Global United Pharmaceutical Corporation

Not yet recruiting

Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults (CREWS01)

Asthma

United States
ICOS Corporation
Suntory Pharmaceutical

Terminated

Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

Sepsis

United States
Oregon Health and Science University
Medicis Pharmaceutical Corporation

Completed

VANOS Cream and Skin Barrier Function

Atopic Dermatitis

United States
Wake Forest University Health Sciences
Medicis Pharmaceutical Corporation

Completed

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis (Vanos)

Atopic Dermatitis

United States
Beer, Kenneth R., M.D., PA
Medicis Pharmaceutical Corporation

Completed

Upper Facial Remodeling With Perlane-L and Dysport (DPL-2010)

Mild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital Rhytids

United States
Biotest Pharmaceuticals Corporation
Biotest

Completed

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma

United States
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Biotest Pharmaceuticals Corporation
Biotest

Completed

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Biotest Pharmaceuticals Corporation
Biotest

Completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Incyte Corporation
Novartis Pharmaceuticals

Completed

A Dose-escalation Study in Subjects With Advanced Malignancies

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Proswell Medical Corporation

Recruiting

A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China

3

Subscribe